Brazil’s swift legislative actions on tirzepatide highlight how emerging markets are increasingly challenging pharmaceutical patents, risking sudden legal exposures under TRIPS flexibilities. The move signals a potential shift in global drug pricing and access strategies.
Brazil’s fast-track vote on tirzepatide has sharpened a legal risk that many drugmakers still treat as remote: a patent can be challenged quickly, and in some cases overridden, under the TRIPS Agreement’s public-health flexibilities. On 9 February 2026, Brazil’s Chamber of Deputies voted 337 to 19 to fast-track legislation declaring tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, a matter of public interest. Days earlier, the Senate had received a separate bill seeking a compulsory licence for the same molecule. Neither proposal is law yet, but the pace of events shows how fast a pricing problem can become a legislative one.
The broader point is that this is not an isolated Brazilian episode. Since the Doha Declaration on TRIPS and Public Health in 2001, governments have repeatedly used compulsory licensing or government-use powers to push down prices on medicines they say are unaffordable or in short supply. The legal basis sits in Article 31 of the TRIPS Agreement, which allows use of a patented invention without the patent holder’s consent if formal steps are followed. A later amendment, Article 31bis, was meant to help countries without manufacturing capacity import medicines made under compulsory licence elsewhere. Yet the practical gap between what the law permits and what countries actually implement remains large, and that gap is where commercial exposure often emerges.
The article’s central warning is that pricing teams tend to underestimate how quickly that exposure can become real. India’s first compulsory licence, issued in 2012 for Bayer’s Nexavar, became the template: the patent office and later the courts relied on evidence that the drug was not reaching enough patients at an affordable price. Thailand’s government-use licences in 2006 and 2007 showed something similar on the political side, where a threatened licence was enough to force price cuts before a formal override. Colombia’s dolutegravir case demonstrated another pattern, in which a country moved after finding that a voluntary licence excluded it from access to a drug already available elsewhere on generic terms.
Taken together, those cases suggest a practical rule: if a company’s own pricing, access or territorial licensing decisions leave a middle-income market outside the voluntary-licence map, that country may eventually appear on a compulsory-licence map instead. Brazil’s tirzepatide bills matter because they extend this logic into a new category of medicines, one centred on high-value metabolic treatment rather than HIV or cancer. Even though the legislation is unresolved, the legislative speed alone is a reminder that patent risk in emerging markets can change overnight, long before a company has finished adjusting its pricing strategy.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
